1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III

Company Pauses OV101 Program Based On NEPTUNE Results

 
• By Alaric DeArment

The Phase III clinical trial showed a noticeable placebo effect compared with OV101.

nerve cells, concept for neurodegenerative and neurological disease
Ovid shifts focus after Phase III Angelman syndrome study disappoints. • Source: Shutterstock

Ovid Therapeutics, Inc. is hitting the pause button on its program to develop OV101 (gaboxadol) for Angelman syndrome following the failure of the Phase III NEPTUNE trial. The company plans a full analysis of trial data and further discussions with the US Food and Drug Administration.

OV101 was Ovid's lead asset, but now the company will turn its attention to OV935 (soticlestat) in Dravet syndrome and Lennox-Gastaut syndrome. Developing the first drug to treat AS, a rare neuro-genetic disorder, was a tall order

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.